Ruplizumab (trade name Antova) is a humanized monoclonal antibody intended for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis.

A study showed that the drug was associated with life-threatening thromboembolisms,[1] while another study only found thrombocytopenia.

[2] Immune activation: Dostarlimab Other: Ibalizumab This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.

You can help Wikipedia by expanding it.